CO5700817A2 - Compuesto pentaciclico heteroaromatico y uso medicinal del mismo - Google Patents
Compuesto pentaciclico heteroaromatico y uso medicinal del mismoInfo
- Publication number
- CO5700817A2 CO5700817A2 CO05110118A CO05110118A CO5700817A2 CO 5700817 A2 CO5700817 A2 CO 5700817A2 CO 05110118 A CO05110118 A CO 05110118A CO 05110118 A CO05110118 A CO 05110118A CO 5700817 A2 CO5700817 A2 CO 5700817A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- optionally substituted
- heteroaromatic ring
- alkyl
- optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- Un compuesto anular heteroaromático de 5 miembros, representado por la fórmula [I]en donde V es =N- o =CH-; W es -S- u -O-; m es 0, 1 ó 2; R1 y R2 son cada uno de manera independiente, un átomo de hidrógeno o un grupo alquilo de C1-4; X es -N(R4)-, -N(R5)-CO-O-, -SO2-N(R5)-, -N(R5)-SO2-, -N(R6)-SO2-N(R5)-, -CO-N(R7)-, -N(R8)-CO-, -N(R9)-CO-N(R5)-, -N(R10)-(CH2)k-N(R5)-, -N(R10)-(CH2)k-N(R5)-CO-, -C(R10)=N-N(R7)-, -N(R10)-(CH2)k-CH(R6)-, -O-, -S- o -SO2- en donde k es 0 o un entero de 1 a 4, R4, R5, R6, R7, R8, R9 y R10 son cada uno de manera independiente (1) un átomo de hidrógeno, (2) un grupo alquilo de C1-6 en donde el grupo alquilo de C1-6 está sustituido opcionalmente por (a) un grupo arilo sustituido opcionalmente, (b) un grupo anular heteroaromático sustituido opcionalmente, (c) un grupo carboxi, (d) un grupo alcoxicarbonilo de C1-4, (e) -CO-N(R15)(R16) en donde R15 y R16 son cada uno de manera independiente, un átomo de hidrógeno, un grupo arilo sustituido opcionalmente, un grupo anular heteroaromático sustituido opcionalmente, un grupo alquilo de C1-6, en donde el grupo alquilo de C1-6 está sustituido opcionalmente por sustituyentes seleccionados del grupo que consiste de un grupo arilo sustituido opcionalmente, un grupo anular heteroaromático sustituido opcionalmente, un grupo alcoxi de C1-4 sustituido opcionalmente por un grupo arilo y un grupo ariloxi sustituido opcionalmente, o, junto con el átomo de nitrógeno unido al mismo, puede formar un anillo de indolina o puede formar un heteroanillo de 5 a 7 miembros que contiene opcionalmente además, al menos un heteroátomo seleccionado del grupo que consiste de un átomo de nitrógeno, un átomo de oxigeno y un átomo de azufre, (f) -N(R15)(R16) en donde R15 y R16 son como se definió anteriormente, (g) -O-R17 en donde R17 es un átomo de hidrógeno, un grupo arilo sustituido opcionalmente, un grupo anular heteroaromático sustituido opcionalmente o un grupo alquilo de C1-6, en donde el grupo alquilo de C1-6 está sustituido opcionalmente por sustituyentes seleccionados del grupo que consiste de un grupo arilo sustituido opcionalmente, un grupo anular heteroaromático sustituido opcionalmente, un grupo alcoxi de C1-4 sustituido opcionalmente por un grupo arilo y un grupo ariloxi sustituido opcionalmente, (h) -CO-R17 en donde R17 es como se definió anteriormente, (i) -SO2-R17 en donde R17 es como se definió anteriormente o (j) un grupo cicloalquilo de C3-7, ...
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003105267 | 2003-04-09 | ||
JP2003157590 | 2003-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5700817A2 true CO5700817A2 (es) | 2006-11-30 |
Family
ID=33161535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05110118A CO5700817A2 (es) | 2003-04-09 | 2005-10-28 | Compuesto pentaciclico heteroaromatico y uso medicinal del mismo |
Country Status (17)
Country | Link |
---|---|
US (1) | US20060122181A1 (es) |
EP (1) | EP1553091A4 (es) |
JP (1) | JP3819415B2 (es) |
KR (1) | KR20050119201A (es) |
AR (1) | AR043860A1 (es) |
AU (1) | AU2004228565A1 (es) |
BR (1) | BRPI0409136A (es) |
CA (1) | CA2521830A1 (es) |
CL (1) | CL2004000778A1 (es) |
CO (1) | CO5700817A2 (es) |
HK (1) | HK1078086A1 (es) |
MX (1) | MXPA05010945A (es) |
NO (1) | NO20055246L (es) |
PE (1) | PE20050018A1 (es) |
RU (1) | RU2005134659A (es) |
TW (1) | TW200500362A (es) |
WO (1) | WO2004089918A1 (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7879840B2 (en) | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
US7718644B2 (en) | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
DE60144284D1 (de) | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
WO2003048140A1 (fr) | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Compose azole et utilisation medicinale de celui-ci |
EP1546110A4 (en) | 2002-07-30 | 2008-03-26 | Univ Virginia | ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE |
WO2005041899A2 (en) | 2003-11-03 | 2005-05-12 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
AU2005236055B2 (en) | 2004-04-20 | 2011-10-06 | Transtech Pharma, Llc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
RU2391340C2 (ru) * | 2004-08-11 | 2010-06-10 | Киорин Фармасьютикал Ко., Лтд. | Новое циклическое производное аминобензойной кислоты |
US7662837B2 (en) * | 2004-10-22 | 2010-02-16 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
US7645755B2 (en) * | 2004-10-22 | 2010-01-12 | Janssen Pharmaceutical N.V. | Inhibitors of c-fms kinase |
WO2006057503A1 (en) * | 2004-11-25 | 2006-06-01 | Lg Life Sciences, Ltd. | NOVEL COMPOUNDS AS AGONIST FOR PPARϜ AND PPARα, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
EP1827606A2 (en) | 2004-12-06 | 2007-09-05 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
JP2008530135A (ja) * | 2005-02-14 | 2008-08-07 | ユニバーシティ オブ バージニア パテント ファンデーション | アミノ基およびフェニル基で置換されたシクロアルカンならびに5員の複素環を含むスフィンゴシン=1−リン酸アゴニスト |
JP2006348024A (ja) * | 2005-05-17 | 2006-12-28 | Santen Pharmaceut Co Ltd | アミジノ誘導体を有効成分として含む神経細胞の保護剤 |
ES2354223T3 (es) * | 2005-05-17 | 2011-03-11 | Santen Pharmaceutical Co., Ltd. | Derivados de amidina para uso en la prevención o el tratamiento de glaucoma. |
US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
AU2007209961A1 (en) | 2006-01-27 | 2007-08-09 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
BRPI0707338A2 (pt) | 2006-01-30 | 2011-05-03 | Transtech Pharma Inc | derivados de imidazol, composições, e métodos substituìdos de uso como inibidores de ptpase |
JP2009526073A (ja) | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン−1−リン酸受容体アナログ |
US8735595B2 (en) | 2006-02-15 | 2014-05-27 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
US8748627B2 (en) | 2006-02-15 | 2014-06-10 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
UA93085C2 (en) | 2006-04-20 | 2011-01-10 | Янссен Фармацевтика Н.В. | Inhibitors of c-fms kinase |
EP2021335B1 (en) | 2006-04-20 | 2011-05-25 | Janssen Pharmaceutica N.V. | Heterocyclic compounds as inhibitors of c-fms kinase |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
WO2008033932A2 (en) * | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors |
MXPA06010973A (es) * | 2006-09-25 | 2009-02-18 | World Trade Imp Export Wtie Ag | Composicion farmaceutica para el tratamiento del sobrepeso y la obesidad que se acompañan la dislipidemia. |
EP2097397A1 (en) | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Tetralin analogs having sphingosine 1-phosphate agonist activity |
EP2099741A2 (en) | 2006-11-21 | 2009-09-16 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
AU2007323557A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
CN101260086B (zh) * | 2007-03-06 | 2011-08-10 | 中国科学院上海药物研究所 | 蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法和用途 |
CL2008000684A1 (es) * | 2007-03-09 | 2008-08-01 | Indigene Pharmaceuticals Inc | Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica. |
TW200848012A (en) * | 2007-03-09 | 2008-12-16 | Indigene Pharmaceuticals Inc | Combination of metformin R-(+)lipoate and antihypertensive agents for the treatment of diabetic hyperglycemia and diabetic complications |
US20100120667A1 (en) * | 2007-04-27 | 2010-05-13 | Nisshin Pharma Inc. | Composition for preventing and/or treating peptic ulcers |
TW200902533A (en) * | 2007-05-02 | 2009-01-16 | Boehringer Ingelheim Int | Carboxylic acid amides, manufacturing and use thereof as medicaments |
US20090011060A1 (en) * | 2007-07-06 | 2009-01-08 | Peter Koepke | Campsiandra angustifolia extract and methods of extracting and using such extract |
US20090017140A1 (en) * | 2007-07-09 | 2009-01-15 | Peter Koepke | Maytenus abenfolia extract and methods of extracting and using such extract |
US20090035395A1 (en) * | 2007-08-01 | 2009-02-05 | Peter Koepke | Spondias mombin l. extract and methods of extracting and using such extract |
US8076491B2 (en) | 2007-08-21 | 2011-12-13 | Senomyx, Inc. | Compounds that inhibit (block) bitter taste in composition and use thereof |
CA2696995C (en) * | 2007-08-21 | 2017-11-21 | Senomyx, Inc. | Identification of human t2r receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof |
US7879369B2 (en) * | 2007-09-18 | 2011-02-01 | Selvamedica, Llc | Combretum laurifolium Mart. extract and methods of extracting and using such extract |
JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
CA2720343A1 (en) * | 2008-04-04 | 2009-10-08 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
JP2012501334A (ja) | 2008-08-29 | 2012-01-19 | トランス テック ファーマ,インコーポレイテッド | 置換アミノチアゾール誘導体、医薬組成物、および使用の方法 |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US20100184722A1 (en) * | 2008-12-19 | 2010-07-22 | Shimoda Biotech (Pty) Ltd | Inclusion complexes of alpha-cyclodextrin and sildenafil salt |
US9724381B2 (en) * | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2012047538A1 (en) | 2010-10-06 | 2012-04-12 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
AU2011323245B2 (en) | 2010-11-05 | 2016-01-21 | Senomyx, Inc. | Compounds useful as modulators of TRPM8 |
PE20140859A1 (es) | 2011-02-25 | 2014-07-25 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos |
EP2844260A4 (en) * | 2012-04-30 | 2016-06-29 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
JP6359537B2 (ja) | 2012-08-07 | 2018-07-18 | ヤンセン ファーマシューティカ エヌ.ベー. | 複素環エステル誘導体の調製プロセス |
CN103044333A (zh) * | 2013-01-11 | 2013-04-17 | 德州翰华医药化学有限公司 | 一种高纯度奥扎格雷钠的制备方法 |
EP2958562A4 (en) | 2013-02-22 | 2016-08-10 | Merck Sharp & Dohme | BICYCLIC ANTIDIABETIC COMPOUNDS |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9326962B2 (en) | 2013-10-22 | 2016-05-03 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
US10813901B2 (en) | 2013-10-22 | 2020-10-27 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
US10751313B2 (en) | 2013-10-22 | 2020-08-25 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
BR112018006471B1 (pt) | 2015-10-01 | 2024-02-27 | Senomyx, Inc | Composto, composição, método de modular o membro de melastina do canal potencial do receptor transitório 8 (trpm8), método de modular a sensação de resfrescância de uma composição e método de induzir uma sensação de refrescância em um ser humano ou animal |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
CN114292224B (zh) * | 2022-03-07 | 2022-05-20 | 中国农业科学院农产品加工研究所 | 一种***二酚-2-(n-乙酰基)哌啶酸酯及其应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5657775A (en) * | 1979-10-17 | 1981-05-20 | Takeda Chem Ind Ltd | Thiazole derivative |
ES2144403T3 (es) * | 1990-11-30 | 2000-06-16 | Otsuka Pharma Co Ltd | Derivados de tiazol como inhibidores de oxigeno activo. |
JP2600644B2 (ja) * | 1991-08-16 | 1997-04-16 | 藤沢薬品工業株式会社 | チアゾリルベンゾフラン誘導体 |
US6080772A (en) * | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
US5770620A (en) * | 1995-06-19 | 1998-06-23 | Ontogen Corporation | Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors |
US5753687A (en) * | 1995-06-19 | 1998-05-19 | Ontogen Corporation | Modulators of proteins with phosphotryrosine recognition units |
TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
FR2754258B1 (fr) * | 1996-10-08 | 1998-12-31 | Sanofi Sa | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
US6011048A (en) * | 1997-01-28 | 2000-01-04 | Merck & Co., Inc. | Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity |
US6063815A (en) * | 1998-05-12 | 2000-05-16 | American Home Products Corporation | Benzopenones useful in the treatment of insulin resistance and hyperglycemia |
US6110962A (en) * | 1998-05-12 | 2000-08-29 | American Home Products Corporation | 11-aryl-benzo[B]naphtho[2,3-D]furans and 11-aryl-benzo[B]naphtho[2,3-D]thiophenes useful in the treatment of insulin resistance and hyperglycemia |
WO1999058514A1 (en) * | 1998-05-12 | 1999-11-18 | American Home Products Corporation | (2-acylaminothiazole-4-yl)acetic acid derivatives |
US6001867A (en) * | 1998-05-12 | 1999-12-14 | American Home Products Corporation | 1-aryl-dibenzothiophenes |
US6110963A (en) * | 1998-05-12 | 2000-08-29 | American Home Products Corporation | Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
US6103708A (en) * | 1998-05-12 | 2000-08-15 | American Home Products Corporation | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia |
US6057316A (en) * | 1998-05-12 | 2000-05-02 | American Home Products Corporation | 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes |
DE69912277T2 (de) * | 1998-05-25 | 2004-07-15 | Taisho Pharmaceutical Co., Ltd. | Prostaglandinderivate |
US20040132788A1 (en) * | 1999-10-11 | 2004-07-08 | Chabrier De Lassauniere Pierre-Etienne | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
US7291641B2 (en) * | 1999-10-11 | 2007-11-06 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
TWI283577B (en) * | 1999-10-11 | 2007-07-11 | Sod Conseils Rech Applic | Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof |
JP2002114768A (ja) * | 2000-10-11 | 2002-04-16 | Japan Tobacco Inc | 2−(2,5−ジハロゲン−3,4−ジヒドロキシフェニル)アゾール化合物及びそれを含有してなる医薬組成物 |
TWI248438B (en) * | 2001-04-10 | 2006-02-01 | Sod Conseils Rech Applic | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments |
WO2003032916A2 (en) * | 2001-10-16 | 2003-04-24 | Structural Bioinformatics Inc. | Organosulfur inhibitors of tyrosine phosphatases |
US6881746B2 (en) * | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
WO2003048140A1 (fr) * | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Compose azole et utilisation medicinale de celui-ci |
AU2005236055B2 (en) * | 2004-04-20 | 2011-10-06 | Transtech Pharma, Llc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
WO2006028970A1 (en) * | 2004-09-02 | 2006-03-16 | Cengent Therapeutics, Inc. | Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
-
2004
- 2004-04-09 WO PCT/JP2004/005119 patent/WO2004089918A1/ja not_active Application Discontinuation
- 2004-04-09 AU AU2004228565A patent/AU2004228565A1/en not_active Abandoned
- 2004-04-09 TW TW093109862A patent/TW200500362A/zh unknown
- 2004-04-09 RU RU2005134659/04A patent/RU2005134659A/ru not_active Application Discontinuation
- 2004-04-09 CA CA002521830A patent/CA2521830A1/en not_active Abandoned
- 2004-04-09 MX MXPA05010945A patent/MXPA05010945A/es not_active Application Discontinuation
- 2004-04-09 BR BRPI0409136-1A patent/BRPI0409136A/pt not_active IP Right Cessation
- 2004-04-09 JP JP2005505323A patent/JP3819415B2/ja not_active Expired - Fee Related
- 2004-04-09 EP EP04726765A patent/EP1553091A4/en not_active Withdrawn
- 2004-04-09 KR KR1020057019180A patent/KR20050119201A/ko not_active Application Discontinuation
- 2004-04-12 AR ARP040101228A patent/AR043860A1/es not_active Application Discontinuation
- 2004-04-12 CL CL200400778A patent/CL2004000778A1/es unknown
- 2004-04-12 PE PE2004000360A patent/PE20050018A1/es not_active Application Discontinuation
-
2005
- 2005-07-07 US US11/176,846 patent/US20060122181A1/en not_active Abandoned
- 2005-10-28 CO CO05110118A patent/CO5700817A2/es not_active Application Discontinuation
- 2005-11-08 NO NO20055246A patent/NO20055246L/no not_active Application Discontinuation
-
2006
- 2006-01-05 HK HK06100204.6A patent/HK1078086A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20060122181A1 (en) | 2006-06-08 |
AU2004228565A1 (en) | 2004-10-21 |
RU2005134659A (ru) | 2007-05-27 |
BRPI0409136A (pt) | 2006-04-25 |
CL2004000778A1 (es) | 2005-01-21 |
CA2521830A1 (en) | 2004-10-21 |
TW200500362A (en) | 2005-01-01 |
NO20055246L (no) | 2005-12-21 |
EP1553091A4 (en) | 2007-01-17 |
WO2004089918A1 (ja) | 2004-10-21 |
JPWO2004089918A1 (ja) | 2006-07-06 |
AR043860A1 (es) | 2005-08-17 |
EP1553091A1 (en) | 2005-07-13 |
HK1078086A1 (zh) | 2006-03-03 |
PE20050018A1 (es) | 2005-03-23 |
KR20050119201A (ko) | 2005-12-20 |
NO20055246D0 (no) | 2005-11-08 |
MXPA05010945A (es) | 2005-11-25 |
JP3819415B2 (ja) | 2006-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5700817A2 (es) | Compuesto pentaciclico heteroaromatico y uso medicinal del mismo | |
MXPA05008619A (es) | Derivados novedosos de 2-piridincarboxamida. | |
ATE293101T1 (de) | Piperidine zur verwendung als orexin rezeptor antagonisten | |
IL164487A0 (en) | 3-Heteroaryl substituted 5-methyloxymethyl isoxazolines used as herbicides | |
NO20066015L (no) | Fuserte heterosykliske forbindelser | |
SE7512477L (sv) | Forfarande for framstellning av heterocykliska foreningar | |
NZ509045A (en) | Intermediates in the formation of antivirally active heterocyclic azahexane derivatives | |
DE60228406D1 (de) | PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS | |
MXPA05009059A (es) | Derivados de heteroarilcarbamoilbenceno. | |
CO5611147A2 (es) | Derivados de nicotinamida utiles como inhibidores p38 | |
SE7908443L (sv) | Heterocykliska foreningar | |
MY159910A (en) | Pyrrolidin-2-one derivatives as androgen receptor modulator | |
MX2009012885A (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco | |
AR011502A1 (es) | Un compuesto substituido de acido 4-hidroxi-fenilalcanoico con actividad agonista a ppar-gamma, un metodo para prepararlo una composicion farmaceutica que lo contiene y uso del compuesto para la fabricacion de un medicamento | |
PE20130155A1 (es) | Derivados de ariletinilo | |
CO5650248A2 (es) | Heterociclos de nitrogeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma | |
AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
AR061058A1 (es) | Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas | |
PE20051159A1 (es) | Derivados de heteroarilaminopirazol como estimulantes de la produccion de insulina | |
FI942635A (fi) | Piperatsiinijohdannaiset 5HT1A-antagonisteina | |
CO5130016A1 (es) | Derivados de dihidrobenzodioxina carboxamida y cetona | |
CO5700777A2 (es) | Derivados de 4-(2-fenilsulfanil-fenil)-1,2,3,6-tetrahidropiridina como inhibidores de la recaptacion de serotonina | |
ES2568909T3 (es) | Novedosos compuestos antagonistas del receptor de la neuroquinina 1 | |
AR039122A1 (es) | Derivados de ftalimido como inhibidores de monoamino oxidasa b | |
AR041481A1 (es) | Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |